Results 81 to 90 of about 12,272 (191)

Safety and efficacy of PCSK9 inhibitors and effect on coronary plaque phenotype in statin-treated patients following acute coronary syndrome: a systematic review and meta-analysis

The Egyptian Heart Journal
Background Acute coronary syndrome continues to be a significant cardiovascular issue. Statins are commonly acknowledged as medications that reduce LDL-C levels and stabilize plaques. Nevertheless, their efficacy is limited.
Dennis Ievan Hakim, Faqrizal Ria Qhabibi, Muhammad Yusuf, Nasim Amar, Indra Prasetya, Ade Meidian Ambari   +5 more
doaj   +1 more source

SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit

Diabetes, Obesity and Metabolism, EarlyView.
Salvatore Corrao, Francesco Cosentino, Massimo Federici   +2 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection

MedComm, Volume 7, Issue 8, August 2026.
EOPC is a distinct clinicopathological entity separable from SOPC, differing fundamentally in genetic susceptibility, TMPRSS2:ERG fusion frequency, and survival outcomes. Although research remains nascent, this review provides the first comprehensive synthesis of current evidence, offering a critical foundation to guide future investigations into this ...
Xingyu Xiong, Weizhen Zhu, Weichao Huang, Shiyu Zhang, Qi Deng, Jie Yang, Hang Xu, Qiang Wei, Lu Yang   +8 more
wiley   +1 more source

Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
Cardiovascular disease arises from lifelong accumulation of traditional and emerging risk factors that converge on shared pathophysiological pathways, leading to diverse clinical outcomes, and can be mitigated through integrated screening, prevention, and precision therapies. ABSTRACT Cardiovascular diseases (CVDs) remain the leading cause of morbidity
Mowei Kong, Zaiyong Zheng, Min Huang, Shengyu Huang, Xingwei Zhao, Yang Yu, Chunxiang Zhang   +6 more
wiley   +1 more source

Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization

PLoS ONE, 2022
Prescription of PCSK9-inhibitors has increased in recent years but not much is known about its off-target effects. PCSK9-expression is evident in non-hepatic tissues, notably the brain, and genetic variation in the PCSK9 locus has recently been shown to ...
Alisha Aman, Eric A. W. Slob, Joey Ward, Breda Cullen, Nicholas Graham, Donald M. Lyall, Naveed Sattar, Rona J. Strawbridge   +7 more
doaj  

The Role of Inflammation and Immunity in Cardiovascular Disease: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 8, August 2026.
Inflammation in cardiovascular disease is a dynamic and context‐dependent network rather than a secondary response to injury. Mitochondrial danger signaling links metabolic stress to immune activation through TLR priming, NLRP3 inflammasome amplification, cGAS–STING signaling, and immunometabolic gating, providing a basis for more precise therapeutic ...
Jiaxiang Rong, Zhen Wang, Xiaoxiao Lin, Ziwen Lei, Qianqian Huang, Hang Liu, Fei Luan, Junbo Zou, Yajun Shi   +8 more
wiley   +1 more source

Therapeutic Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Althea Medical Journal
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel class of medications for managing dyslipidemia. Although previous meta-analyses have confirmed their efficacy in lowering low-density lipoprotein cholesterol ...
Nur Hafidha Hikmayani, Ratih Puspita Febrinasari, Ariq Ratya Satwika   +2 more
doaj   +1 more source

Amino Acid and Lipid Metabolism in Cancer: Mechanisms and Therapeutic Opportunities

MedComm, Volume 7, Issue 8, August 2026.
Amino Acid and lipid metabolism in cancer: (A) Regulation of Amino acid transportation and metabolism in cancer. (B) The core organization of lipid metabolic reprogramming in cancer and their functional consequences. ABSTRACT Metabolic reprogramming is a defining feature of cancer and a major contributor to immune escape.
Zixu Wang, Xin Fu, Jingchao Bai, Yanguo Liu, Kai Huang   +4 more
wiley   +1 more source

PCSK9 inhibition: from effectiveness to cost-effectiveness

Frontiers in Cardiovascular Medicine
Dyslipidaemia is a complex disorder characterised by abnormal lipid levels in the blood, including cholesterol and triglycerides, and plays an important role in the development of atherosclerotic cardiovascular disease.
Iveta Mercep, Iveta Mercep, Dominik Strikic, Pero Hrabac, Ivan Pecin, Željko Reiner, Željko Reiner   +6 more
doaj   +1 more source